Abstract:Mammalian circadian rhythms result from a complex organization involving molecular clocks within nearly all "normal" cells and a dedicated neuroanatomical system, which coordinates the so-called "peripheral oscillators." The core of the central clock system is constituted by the suprachiasmatic nuclei that are located on the floor of the hypothalamus. Our understanding of the mechanisms of circadian rhythm generation and coordination processes has grown rapidly over the past few years. In parallel, we have learnt how to use the predictable changes in cellular metabolism or proliferation along the 24h time scale in order to improve treatment outcome for a variety of diseases, including cancer. The chronotherapeutics of malignant diseases has emerged as a result of a consistent development ranging from experimental, clinical, and technological prerequisites to multicenter clinical trials of chronomodulated delivery schedules. Indeed large dosing-time dependencies characterize the tolerability of anticancer agents in mice or rats, a better efficacy usually results from treatment administration near the least toxic circadian time in rodent tumor models. Programmable in time multichannel pumps have allowed to test the chronotherapy concepts in cancer patients and to implement chronomodulated delivery schedules in current practice. Clinical phase I and II trials have established the feasibility, the safety, and the activity of the chronotherapy schedules, so that this treatment method has undergone further evaluation in international multicenter phase III trials. Overall, more than 2,000 patients with metastatic disease have been registered in chronotherapy trials. Improved tolerability and/or better antitumor activity have been demonstrated in randomized multicenter studies involving large patient cohorts. The relation between circadian rhythmicity and quality of life and even survival has also been a puzzling finding over the recent years. An essential step toward further developments of circadian-timed therapy has been the recent constitution of a Chronotherapy cooperative group within the European Organization for Research and Treatment of Cancer. This group now involves over 40 institutions in 12 countries. It is conducting currently six trials and preparing four new studies. The 19 contributions in this special issue reflect the current status and perspectives of the several components of cancer chronotherapeutics.

Chronobiology of Cancers in the Liver and Gut

The Role of Circadian Rhythm in the Pathogenesis of Colorectal Cancer

New Insights Into Cancer Chronotherapies

Circadian rhythms and new options for novel anticancer therapies

Circadian Timing in Cancer Treatments

From circadian rhythms to cancer chronotherapeutics

Circadian Clock and Liver Cancer

Circadian clocks in health and disease: Dissecting the roles of the biological pacemaker in cancer

Circadian rhythms of liver physiology and disease: experimental and clinical evidence

Circadian Rhythms in Liver Physiology and Liver Diseases

Circadian Clock Control of Liver Metabolic Functions

Circadian clock and lipid metabolism disorders: a potential therapeutic strategy for cancer

Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer

Circadian rhythm as a key player in cancer progression as well as a therapeutic target in HER2-positive advanced gastric cancer treatment

Chronobiology of the Tumor Microenvironment: Implications for Therapeutic Strategies and Circadian-Based Interventions

Circadian rhythms and cancers: the intrinsic links and therapeutic potentials

Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology

The role of the circadian clock in cancer hallmark acquisition and immune-based cancer therapeutics

The Circadian Clock as a Potential Biomarker and Therapeutic Target in Gastrointestinal Cancers

Roles of circadian clocks in cancer pathogenesis and treatment